FFR, iFR, CFR, and IMR: Results from clinical trials

Cathevine Yang1, Christopher Wong1, Kosei Teradaa1

  • 1Stanford University, Department of Medicine, Division of Cardiovascular Medicine, Stanford, CA, USA.

Insights

This review explores fractional flow reserve (FFR), instantaneous wave-free ratio (iFR), coronary flow reserve (CFR), and index of microvascular resistance (IMR) for diagnosing and managing coronary microvascular dysfunction, noting their limitations and emerging applications.

Area of Science:

  • Cardiology
  • Vascular Physiology
  • Diagnostic Imaging

Background:

  • Coronary microvascular dysfunction (CMD) is increasingly recognized as a significant contributor to ischemic heart disease.
  • Accurate diagnosis and management of CMD are crucial for improving patient outcomes.
  • Current diagnostic tools and therapeutic strategies for CMD require further refinement.

Purpose of the Study:

  • To provide a comprehensive overview of key physiological indices used in assessing coronary artery disease.
  • To discuss the definition, application, and limitations of FFR, iFR, CFR, and IMR in the context of CMD.
  • To review recent evidence and emerging clinical indications for these indices in various cardiovascular conditions.

Main Methods:

  • Systematic review of current literature on FFR, iFR, CFR, and IMR.
  • Analysis of diagnostic and prognostic performance of these indices in CMD.
  • Evaluation of their utility in managing epicardial and microvascular coronary artery disease.

Main Results:

  • FFR, iFR, CFR, and IMR offer valuable insights into coronary hemodynamics and microvascular function.
  • Each index has specific limitations that must be considered in clinical practice.
  • Emerging evidence supports their use in acute myocardial infarction, heart failure with preserved ejection fraction, and post-transplant settings.

Conclusions:

  • FFR, iFR, CFR, and IMR are essential tools for evaluating CMD, complementing traditional angiography.
  • Understanding their limitations and appropriate application is key to optimizing patient care.
  • Further research is warranted to fully elucidate their role in complex cardiovascular scenarios.

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
431
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
756